Fresh analysis suggests that people who come off blockbuster weight-loss injections like semaglutide or tirzepatide can put back on reduced body mass much more quickly than those who end conventional lifestyle regimens.
Findings released in a leading medical journal demonstrates that while overweight people frequently drop substantial amounts of their total mass while undergoing treatment, the mass comes back at an estimated rate of 0.8 kg per month after stopping.
"People purchasing such medications should be cognizant of the danger of rapid rebound weight gain when the therapy is stopped," cautioned researcher Dr. Susan Jebb.
This pace of recovery suggests a reversion to pre-treatment mass within about 18 months.
Comparing Therapies
The analysis, which reviewed 37 of trials involving thousands of patients, compared the effects of GLP-1 agonists with conventional dieting.
The team note that people who lose weight through dieting typically have a slower creep back—around 100 grams monthly—once they finish.
Explaining the Fast Regain
Nutrition scientists believe the mode of action of the injections accounts for the amplified regain.
These medications imitate a body's own chemical called glucagon-like peptide-1, which helps regulate feelings of fullness.
"Artificially providing GLP-1 levels several times higher than the body's typical production might result in the body to generate a reduced amount of its own natural hormone, and may also reduce responsiveness to its effects," noted Dr. Adam Collins, a dietetics researcher.
"Stopping of this hormone supplement leads to hunger is no longer kept in check, making excessive eating much more probable."
A Lifelong Disease?
Medical guidelines advise the injections for people with obesity-related health risks, accompanied by recommended lifestyle changes.
Professionals contend that, due to the likelihood of relapse, the treatment might need to be ongoing.
This perspective is supported by pharmaceutical companies, who say that the findings "underscore the long-term nature of obesity," comparing it to managing diseases like hypertension.
Patient Accounts
Users who have stopped the medication explain a powerful return of hunger.
"It was like a switch activating and you become ravenous," described a patient.
This challenge is worsened if patients have not developed lasting dietary or behavioural modifications during therapy.
Significant Interest
Survey data indicate that a significant number of people in the UK have used weight-loss jabs in the past year, with desire being substantial.
- Use is higher among females compared to males.
- The middle-aged age group shows the highest level of interest.
- Many access the drugs through private healthcare rather than public health services.
In conclusion, clinicians stress that while the jabs are effective agents for shedding pounds, they are not a standalone solution and lasting health benefits hinges on ongoing lifestyle changes.
